Nektar Therapeutics

NKTR · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.3%

Institutions106.4%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$55.23M	$98.43M	$92.06M	$101.91M	$152.91M	$114.62M	$1.19B	$307.71M	$165.44M	$190.38M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$0	$30.69M	$21.64M	$24.90M	$19.48M	$21.37M	$24.41M	$30.55M	$30.21M	$34.10M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$140.10M	-$105.20M	-$376.17M	-$446.10M	-$425.11M	-$440.04M	$687.93M	-$59.64M	-$112.86M	-$29.37M
Operating income as a percentage of revenue.	-253.7%	-106.9%	-408.6%	-437.8%	-278.0%	-383.9%	57.6%	-19.4%	-68.2%	-15.4%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$164.08M	-$118.96M	-$368.20M	-$523.84M	-$444.44M	-$440.67M	$681.31M	-$96.69M	-$153.52M	-$81.18M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-9.00	$0.00	$-1.00	$-2.86	$-2.49	$-2.00	$4.00	$0.00	$-1.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-9.00	$0.00	$-1.00	$-2.86	$-2.49	$-2.00	$3.00	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$15.12M	$44.25M	$88.23M	$25.22M	$198.96M	$96.36M	$194.91M	$4.76M	$59.64M	$55.57M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$280.41M	$303.85M	$710.60M	$1.12B	$1.54B	$1.98B	$2.15B	$508.87M	$568.87M	$502.06M
Everything the company owes — debt, unpaid bills, and other obligations.	$190.57M	$243.11M	$343.96M	$437.68M	$461.47M	$571.97M	$432.60M	$421.04M	$480.75M	$495.63M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$89.83M	$60.74M	$366.64M	$679.51M	$1.08B	$1.41B	$1.72B	$87.83M	$88.13M	-$1.87B

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$208.51M	-$175.71M	-$304.01M	-$412.66M	-$313.29M	-$328.68M	$718.21M	-$80.41M	-$117.02M	-$73.08M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$171000	$1.47M	$5.68M	$14.99M	$7.26M	$26.29M	$14.24M	$9.68M	$6.39M	$11.20M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$208.68M	-$177.18M	-$309.68M	-$427.65M	-$320.55M	-$354.97M	$703.98M	-$90.09M	-$123.42M	-$84.28M

	You	Peer avg
P/E	–	17.7
Revenue Growth	-9.3%	+3.6%
ROE	-35.8%	-7.9%

Nektar Therapeutics

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison